Income StatementBalance SheetCash FlowSegments
Roivant Sciences logo

Roivant Sciences Cash Flow Statement

Operating, investing, and financing cash movements

Roivant Sciences generated -$750.3M in operating cash flow over the trailing twelve months. After $14.0M in capital expenditures, free cash flow was -$758.6M. Free cash flow increased 0.1% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)-$750.3MNet Cash From Investing (TTM)$1.9BNet Cash From Financing (TTM)-$746.9MCapital Expenditures (TTM)$14.5MDepreciation And Amortization Cf (TTM)$3.3MNet Change In Cash (TTM)-$4.5B
Latest FilingQ1 2026
Report Date2026-05-20
Market Cap$21.6B

Operating

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Other non-cash income (expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Amortization of Investment Discount and Premium$29.3M$15.7M$11.1M$9.8M$8.7M—
Accretion (amortization) of discounts and premiums on investments$29.3M$15.7M$11.1M$9.8M$8.7M—
Change in accounts payable—-$165.0K-$11.7M$3.0M-$4.0M$16.2M
Change in accrued liabilities-$3.0M—-$25.0M——$63.2M
Change in income taxes payable/receivable-$2.5M-$2.5M$21.3M$21.3M$21.3M$21.3M
Change in operating lease liabilities-$2.0M-$241.0K-$478.0K-$846.0K-$786.0K-$275.0K
Change in other assets$2.2M$2.2M$1.9M$1.9M$1.9M$1.9M
Change in other current assets$41.7M—-$128.0K$4.4M$2.7M-$18.5M
Change in other liabilities$193.3K$193.3K-$252.0K-$252.0K-$252.0K-$252.0K
Other working capital changes$6.4M-$18.4M$71.0K$3.2M-$8.3M—
Depreciation and amortization$2.9M$1.4M$1.1M$921.0K$691.0K$638.0K
Net gains (losses) on investments-$21.3M$12.9M-$19.1M$128.5M$21.6M—
Accretion (Amortization) of Investment Discounts and Premiums$29.3M$15.7M$11.1M$9.8M$8.7M—
Other Non-Cash Income (Expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Loss on extinguishment of debt-$2.2M-$2.2M———$0.0
Other Non-cash Income (Expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Other Non-cash Income (Expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Net cash from operating activities-$207.3M-$172.6M-$204.4M-$185.7M-$196.5M-$163.8M
Net income$118.1M-$252.4M-$223.4M-$166.0M-$313.7M—
Other non-cash income (expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Accretion (Amortization) of Discounts and Premiums, Investments$29.3M$15.7M$11.1M$9.8M$8.7M—
Gain (Loss) on Fair Value of Debt and Liability Instruments—$14.1M-$2.3M-$21.0M-$24.4M$0.0
Gain (Loss) on Investments-$21.3M$12.9M-$19.1M$128.5M$21.6M—
Gain on sale of Telavant net assets$0.0$0.0$0.0$0.0$0.0$0.0
Gain on sale of subsidiary interests$94.1M$94.1M———$0.0
Accounts payable—-$165.0K-$11.7M$3.0M-$4.0M$16.2M
Increase (Decrease) In Litigation Settlement Receivables$0.0$0.0$192.6M$192.6M$192.6M$192.6M
Operating lease liabilities-$2.0M-$241.0K-$478.0K-$846.0K-$786.0K-$275.0K
Increase (Decrease) in Other Current Assets$41.7M—-$128.0K$4.4M$2.7M-$18.5M
Non-cash operating lease expense$1.7M$2.0M$1.9M$1.9M$2.5M$1.9M
Lease impairment charges—$0.0$3.9M$3.9M$3.9M$3.9M
Operating lease right-of-use asset amortization$1.7M$2.0M$1.9M$1.9M$2.5M$1.9M
Other Noncash Income (Expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Other Non-cash Income and Expense-$11.9M-$4.2M-$11.1M-$6.0M——
Other Non-Cash Adjustments-$11.9M-$4.2M-$11.1M-$6.0M——
Other Non-Cash Income and Expense-$11.9M-$4.2M-$11.1M-$6.0M——
Accretion (Amortization) of Investment Discounts and Premiums$29.3M$15.7M$11.1M$9.8M$8.7M—
Stock-based compensation$83.7M$83.5M$82.2M$81.8M$105.0M$77.2M
Change in Interest Payable$0.0$0.0$0.0$0.0$0.0$0.0

Investing

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Net Cash Divested from Deconsolidation$31.1M$74.0K———$4.4M
Capital expenditures$1.8M$811.0K$4.0M$7.8M—$1.3M
Payment for (Proceeds from) Other Investing Activity$0.0-$79.0K$629.5K$629.5K$629.5K$629.5K
Payments to Acquire Held-to-Maturity Securities$1.0B$1.0B$0.0$0.0$0.0$0.0
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale$0.0$0.0$280.6M$280.6M$280.6M$280.6M
Proceeds from sale of Telavant net assets, net$27.6M$27.6M———$0.0
Net cash from investing activities——-$1.1B———
Other investing activities$0.0-$79.0K$629.5K$629.5K$629.5K$629.5K
Proceeds from sale of businesses$75.2M$75.0M——$0.0$0.0
Purchases of fixed maturity securities$1.0B$1.0B$0.0$0.0$0.0$0.0
Paydowns and maturities of HTM securities$490.0M$490.0M$546.3M$546.3M$546.3M$546.3M

Financing

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Finance Lease, Principal Payments$112.0K$0.0$0.0$0.0$0.0$0.0
Payments Of Taxes For The Repurchase Of Equity$8.6M$7.5M$9.5M$6.5M$23.9M$8.8M
Proceeds from issuance of subsidiary common shares, net of issuance costs paid—$112.8M$48.4M$48.4M$48.4M$48.4M
Contribution from minority interest holder to subsidiary—$0.0——$39.3M—
Proceeds From Divestiture Of Interest In Consolidated Subsidiaries$75.2M$75.0M——$0.0$0.0
Proceeds from issuance of common stock relating to employee stock plans—$380.0K——$381.0K—
Repayment Of Long Term Debt And Convertible Debt By Subsidiary$49.0M$0.0$0.0$0.0$0.0$0.0
Finance lease prepayments$112.0K$0.0$0.0$0.0$0.0$0.0
Net cash from financing activities-$273.0M-$177.2M-$187.8M—$328.2M—
Payments for finance leases$112.0K$0.0$0.0$0.0$0.0$0.0
Proceeds from issuance of common stock$0.0$0.0$30.1M$68.3M$118.8M-$217.2M
Repurchases of common stock$243.3M$295.4M$208.3M———

Free Cash Flow

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Free cash flow-$209.1M-$173.4M-$208.4M-$193.5M-$191.5M-$165.1M

Other

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Effect of exchange rate changes on cash——$815.0K$1.2M$430.0K$1.3M
Net increase (decrease) in cash-$27.2M—-$1.5B-$1.4M—-$57.8M
Issuance Of Subsidiary Shares In Connection With Debt Renegotiation$0.0$23.3M$0.0$0.0$0.0$0.0
Noncash Other——$44.0K-$14.8M——
Operating Lease Right-of-use Assets Obtained and Exchanged for Operating Lease Liabilities—-$98.0K———-$464.0K
Reclassification of earn-out shares liability to additional paid-in capital upon vesting—$0.0$14.4M$14.4M$14.4M$14.4M
Taxes payable related to net settlement of equity awards$0.0$0.0$7.8M$7.8M$7.8M$7.8M

Supplemental

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Interest paid$1.5M$1.5M$0.0$0.0$0.0$0.0